ArticleJournal of neurology2025
Impact of LRRK2 and GBA variants on orthostatic hypotension in patients with Parkinson's disease.
Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association between cerebrospinal fluid LRRK2 and incident orthostatic hypotension differs by genetic background in Parkinson's disease.Acta neurologica Belgica · 2026Article
- The interplay between GBA1 status and age of onset on cognitive, motor and non-motor outcomes in Parkinson's disease: multicenter cross-sectional study.Journal of neurology · 2026Article
- Approach to Cardiovascular Autonomic Dysfunction in Patients with Synucleinopathies.Movement disorders clinical practice · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroudOrthostatic hypotension (OH) is not rare in patients with Parkinson's disease (PD). To date, there have been few studies on the association of genetic variants with OH.
objectivesWe aimed to evaluate the association of LRRK2 and GBA variants with OH in a large PD cohort.
methodsThis study utilized data from the PPMI database, including 863 participants who were divided into the sporadic PD patients (sPD, n = 357), GBA variant carriers (GBA-PD, n = 137), LRRK2 variant carriers (LRRK2-PD, n = 158) and healthy controls (HC, n = 211). LRRK2-PD patients were additionally categorized into G2019S (n = 141) and R1441G (n = 16). GBA-PD patients were categorized into three subgroups by the genomic categorization.
resultsNo significant difference was found in the incidence of OH among the four groups at baseline. Lower University of Pennsylvania Scent Identification Test (UPSIT) scores, higher Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire (RBDSQ) score and the risk GBA mutations were significantly associated with OH cross-sectionally. Higher Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) total and part II scores, higher Epworth Sleepiness Scale (ESS) scores, higher RBDSQ scores and higher Scales for Outcomes in Parkinson's Disease-Autonomic Questionnaire (SCOPA-AUT) scores were strongly linked with OH progression over time. LRRK2 mutations especially LRRK2 G2019S mutation were significantly associated with the lower risk of OH progression.
conclusionLRRK2-PD, particularly the LRRK2-G2019S-PD, were found to have a lower risk of OH. In contrast, the role of GBA mutations in OH appears more complex, with no further evidence to suggest that GBA is associated with the progression of OH in PD.
Indexed as
Identifiers
40314780What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.